Drug Search Results
More Filters [+]

IGM-2644

Alternative Names: IGM-2644, IGM2644, IGM 2644
Latest Update: 2024-09-30
Latest Update Note: News Article

Product Description

IGM-2644 is a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. IGM plans to file an IND application in 2022 with the U.S. Food and Drug Administration (FDA) for IGM-2644 to begin clinical testing in multiple myeloma. (Sourced from: https://igmbio.com/pipeline/igm-2644/)

Mechanisms of Action: CD38 Inhibitor,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IGM Biosciences
Company Location: MOUNTAIN VIEW CA 94043
Company CEO: Fred Schwarzer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IGM-2644

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Multiple Myeloma

Phase 0: Autoimmune Disease Unspecified|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IGM-2644-001

P1

Terminated

Multiple Myeloma

2024-02-16

Recent News Events